Pyronaridine-artesunate
Sponsors
Medicines for Malaria Venture, University of Oxford, Royal Tropical Institute, Shin Poong Pharmaceutical Co. Ltd.
Conditions
COVID-19MalariaMalaria, FalciparumUncomplicated Plasmodium Falciparum Malaria
Phase 1
Phase 2
Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria
CompletedNCT00331136
Start: 2006-06-30End: 2006-12-31Updated: 2022-05-05
Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria
CompletedNCT02389439
Start: 2015-03-01End: 2016-06-01Updated: 2018-09-20
The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
CompletedNCT04475107
Start: 2020-07-09End: 2021-04-15Updated: 2021-06-01
Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19
CompletedNCT04532931
Start: 2020-09-03End: 2021-08-23Updated: 2025-07-28